Liquid Biopsy Opening Up New Possibilities in the Cancer Diagnostics

07 Dec 2017
Global liquid biopsy market

Liquid biopsy is gaining traction in the healthcare and medical research as it has provided an efficient and non-invasive method of screening and diagnostic in oncology. This field is continuously unfolding new possibilities in the healthcare system. Researchers at The University of Texas at Austin are developing a new tool for liquid biopsy that will be able to provide doctors with a clearer picture of an individual’s disease, improving their chances of finding the best treatment. Alan Lambowitz, a professor in the Institute for Cellular and Molecular Biology and the Department of Molecular Biosciences, and his team are studying an ancient enzyme in bacteria that can be used to detect bits of genetic material shed by cancer or other diseased cells into a patient’s bloodstream. This ancient enzyme is a Molecular Cell, which detects the full range of RNAs with much higher accuracy, which, in turn, is helpful for understanding both the general profile of a disease such as cancer and specific information about its activity in a particular patient.1

The European Union is investing €6.3m into the blood diagnosis of primary breast cancer and rectal cancer. In the 4-year LIMA project, Royal Philips will lead an SME consortium that combines liquid biopsy of circulating tumor cells (CTCs) with Magnetic Resonance Imaging (MRI). This project complements the €18.3m Cancer-ID project, in which Big Pharma-led technology companies and academic researchers seek to assess the feasibility of different liquid biopsy techniques to diagnose breast and colon cancer. The Horizon 2020-funded "Liquid biopsies and IMAging for improved cancer care" (LIMA) project is focussed on increasing the accuracy of genetic and functional characterization of primary breast cancer and rectal cancer cells, harvested from blood with British Angle plc' Parsortix system. LIMA participants will combine Philips MRI know-how with cell-based and DNA-based liquid biopsy techniques to develop an integrated, clinically tested approach for personalized cancer treatment.2

ANGLE PLC announced in the second-half of November 2017 that it has entered into a collaboration with Koninklijke Philips NV to develop liquid biopsy products. Angle added that it will receive GBP 400, 000 of a EUR 6.3 million research grant that Philips has secured. Amsterdam-based Philips has chosen ANGLE's Parsortix system as its sole system for harvesting circulating tumor cells for analysis in the research collaboration, which is planned for a four-year period.3

Acknowledging the rapidly growing popularity of liquid biopsy in the healthcare market, BIS Healthcare has compiled a report titled ‘Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025’. According to the market research report, the global liquid biopsy market is expected to grow over $4.43 billion by 2025.Most of the companies providing liquid biopsy tests have limited their operations to the developed markets, leaving large potential of emerging markets untapped. The countries such as China, Japan, India, Australia, and South Africa possess population with high risk of developing mutations in high numbers and offer a great opportunity for the expansion of the liquid biopsy market.

References:                                                                                                

UT News

European Biotechnology

Interactive Investor

 

Recent News

12 Jun 2018

Intensive Competition Among Key Players in the Market for Cathode Materials

According to the latest market intelligence report..


07 Jun 2018

Global Cell Free DNA Isolation and Extraction Market- Analysis and Forecasts (2018-2026)

According to the latest market intelligence report..

NEWSLETTER SIGNUP

 

Upcoming Events

Strategic Analysis of Precision Medicine, Forecast of Future Trends

https://www.gii.co.jp/seminar/bis-seminar2018 When: 02 Oct - 02 Oct, 2018
  Where: Otemachi Sankei Plaza, 1-7-2 Otemachi Chiyoda
Representative- Global Information, Inc. (GII)
Type of Engagement- Speaker

10th World Congress on Precision and Personalized Medicine

https://personalized-medicine.conferenceserie When: 05 Oct - 06 Oct, 2018
  Where: Osaka, Japan
Type of Engagement- Attendees

Twitter Feeds

 

OUR CLIENTS

Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors